Comparing Results of Five Glomerular Filtration Rate-Estimating Equations in the Korean General Population: MDRD Study, Revised Lund-Malmö, and Three CKD-EPI Equations

Misuk Ji, M.D.1,*, Yoon-Hee Lee, M.T.2,*, Mina Hur, M.D.3, Hyesun Kim, M.T.2, Han-Ik Cho, M.D.2, Hyun Suk Yang, M.D.4, Silvia Navarin, M.D.5, and Salvatore Di Somma, M.D.5; on Behalf of GREAT Network

Department of Laboratory Medicine1, Veterans Health Service Medical Center, Seoul; Korea Association of Health Promotion2, Seoul; Departments of Laboratory Medicine3 and Cardiovascular Medicine4, Konkuk University School of Medicine, Seoul, Korea; Department of Medical Sciences and Translational Medicine5, University of Rome Sapienza, Sant’Andrea Hospital, Rome, Italy

Background: Estimated glomerular filtration rate (eGFR) is a widely used index of kidney function. Recently, new formulas such as the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations or the Lund-Malmö equation were introduced for assessing eGFR. We compared them with the Modification of Diet in Renal Disease (MDRD) Study equation in the Korean adult population.

Methods: The study population comprised 1,482 individuals (median age 51 [42-59] yr, 48.9% males) who received annual physical check-ups during the year 2014. Serum creatinine (Cr) and cystatin C (CysC) were measured. We conducted a retrospective analysis using five GFR estimating equations (MDRD Study, revised Lund-Malmö, and Cr and/or CysC-based CKD-EPI equations). Reduced GFR was defined as eGFR <60 mL/min/1.73 m².

Results: For the GFR category distribution, large discrepancies were observed depending on the equation used; category G1 (≥90 mL/min/1.73 m²) ranged from 7.4-81.8%. Compared with the MDRD Study equation, the other four equations overestimated GFR, and CysC-based equations showed a greater difference (-31.3 for CKD-EPI_CysC and -20.5 for CKD-EPI_Cr-CysC). CysC-based equations decreased the prevalence of reduced GFR by one third (9.4% in the MDRD Study and 2.4% in CKD-EPI_CysC).

Conclusions: Our data shows that there are remarkable differences in eGFR assessment in the Korean population depending on the equation used, especially in normal or mildly decreased categories. Further prospective studies are necessary in various clinical settings.

Key Words: Estimated glomerular filtration rate, MDRD Study equation, CKD-EPI equation, Revised Lund-Malmö equation

INTRODUCTION

Early detection of at-risk populations with decreased kidney function is important for both acute kidney injury and chronic kidney disease (CKD) [1-3]. Glomerular filtration rate (GFR) is the most widely used index for assessing kidney function, which is implicated in the guidelines for CKD diagnosis and staging [3-6]. Various equations for estimating GFR (eGFR) have been introduced and are currently used; among them, 83% of clinical laboratories used the serum creatinine (Cr)-based Modification of Diet in Renal Disease (MDRD) Study equation in the 2013 College of American Pathologists survey [7]. However, the equa-
tion was derived from subjects with CKD, and had the limitation of systematically underestimating GFR in healthy individuals with GFR ≥60 mL/min/1.73 m² [8, 9]. To overcome this limitation, the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPIcys) was developed in 2009 on the basis of serum Cr, and more accurate calculations for GFRs ≥60 mL/min/1.73 m² were made possible [10]. In addition, CKD-EPI 2012 equations based on cystatin C (CysC) (CKD-EPIcys) or a combination of Cr and CysC (CKD-EPIcys-CysC) were proposed in a standardized assay to better estimate GFR [11, 12]. Another new equation, the revised Lund-Malmö (LM-revised) equation was recently developed, and its performance was reported to be more consistent than the MDRD Study and CKD-EPI equations [13-15]. However, this equation was derived from only a Swedish Caucasian population.

There have been several reports that compared the MDRD Study and CKD-EPI equations in the general population [16-20]; however, only a few studies have included the CysC-containing equations. In this study, we compared five eGFR equations (MDRD Study equation, LM-revised equation, and three CKD-EPI equations) to explore the differences in the equations across the GFR categories in Korean adults.

**METHODS**

1. Study population

During the year 2014, the recipients of annual physical check-ups at the Gangnam branch of Korean Association of Health Promotion (KAHP, Seoul, Korea) were consecutively included according to the following criteria: over 30 yr old and presence of serum Cr and/or CysC results. There were no exclusion criteria for the subject selection process. KAHP is a specialized health-screening center, which provides routine medical check-ups to over 1,000,000 individuals annually in 16 branch clinics nationwide in Korea.

The number of subjects with serum Cr and CysC results was 1,482 (51 [42-59] yr, 48.9% males). Besides serum Cr and/or CysC results, lipid profiles and HbA1c levels were also collected. We conducted a retrospective analysis of laboratory data using the five eGFR equations, and this study was approved by the Institutional Review Board of KAHP.

2. Estimation of GFR

GFR (mL/min/1.73 m²) was estimated by using five different equations (MDRD Study, LM revised, and three CKD-EPI equations) as follows:

- a) Four-variable MDRD Study equation [9], \( \text{GFR} = 175 \times \text{Cr}^{-1.154} \times \text{Age}^{-0.203} \times 0.742 \) (if female);
- b) LM-revised equation [13], \( \text{GFR} = e^{-0.0138 \times \text{Age} - 0.438 \times \ln(\text{Age})} \); where ln is natural logarithm and \( X = 2.50 + 0.0121 \times (150 - \text{Scr}) \) for females with sCr level < 150 μmol/L, 2.50 - 0.926 \times \ln(sCr/150) for females with sCr level ≥ 150 μmol/L, 2.56 + 0.00968 \times (180 - sCr) for males with sCr level < 180 μmol/L, and 2.56 - 0.926 \times \ln(sCr/180) for males with sCr level ≥ 180 μmol/L;
- c) CKD-EPI-Cys equation [10], \( \text{GFR} = 141 \times \min(\text{sCr} / \kappa, 1) \times \max(\text{sCr} / \kappa, 1.1^{2.09} \times 0.993^{\alpha} \times 1.018) \) (if female), where sCr is serum creatinine, \( \kappa \) is 0.7 for females and 0.9 for males, \( \alpha \) is -0.329 for females and -0.411 for males, min is the minimum of sCr/κ or 1, and max is the maximum of sCr/κ or 1;
- d) CKD-EPIcys equation [11], \( \text{GFR} = 133 \times \min(\text{sCysC} / 0.8, 1) \times \max(\text{sCysC} / 0.8, 1.1^{2.09} \times 0.996^{\delta} \times 0.932) \) (if female), where sCysC is serum cystatin C, \( \kappa \) is 0.7 for females and 0.9 for males, \( \alpha \) is -0.248 for females and -0.207 for males.

Serum Cr levels were determined by the kinetic Jaffe method using SICDIA CRE reagent (Shinyang Chemical, Seoul, Korea) on an automated chemistry analyzer (HITACHI 7600-110; Hitachi High-Technologies Co., Tokyo, Japan). Isotope-dilution mass spectrometry (IDMS)-traceable calibration was conducted weekly with a C.f.a.s. calibrator (Roche Diagnostics, Indianapolis, IN, USA). For internal quality control in the Cr assay, two levels of Dynochek assayed chemistry quality control materials (Bio-Rad, Hercules, CA, USA) were tested once a day. The mean within-laboratory precision of the serum Cr assay was 2.1% during the study period. The laboratory participated in the external proficiency testing program organized by the Korean Association of Quality Assurance for Clinical Laboratory, and the results were all acceptable (variance index scores < 150) during 2014.

Serum CysC levels were measured by the latex immunoturbidimetric method using Sekisui reagent (Sekisui Chemical, Tokyo, Japan) on the same analyzer. The reagent was traceable to the European Reference Material DA471/IFCC. Two levels of Liquichek Immunology Control materials (Bio-Rad) were tested once a day. The mean within-laboratory precision of the serum CysC assay was 1.4% during the study period. The inter-laboratory comparison was performed for CysC, and the differences in results between the two locations were within 10%. All measurements were performed according to the manufacturer’s in-
structions and standard laboratory procedures.

3. GFR categories
GFRs were categorized into ≥90 (G1), 60-89 (G2), 45-59 (G3a), 30-44 (G3b), 15-29 (G4), and <15 (G5) mL/min/1.73 m² according to the Kidney Disease Improving Global Outcomes (KDIGO) 2012 guideline [4]. The prevalence of reduced GFR, defined as eGFR <60 mL/min/1.73 m², was compared among the equations on the basis of the levels of serum Cr, CysC, or both [4].

4. Statistical analyses
The eGFRMDRD was regarded as the comparative GFR for comparisons. Bland-Altman plots were used to identify mean differences and 95% limits of agreement of eGFRs between each equation and the MDRD Study equation. Pearson’s correlation coefficients (r) were calculated to compare the equations. r coefficients ≤0.35 were considered low or weak correlations; 0.36-0.67, modest or moderate correlations; and 0.68-1.0, strong or high correlations; with r coefficients ≥0.90 being very high correlations [21].

Categorical agreement rates were calculated when eGFRMDRD and eGFR based on other equations were within the same GFR categories. Weighted kappa value was determined to evaluate the degree of categorical agreement, and kappa value was determined for diagnostic agreement with GFR cutoffs of 60 mL/min/1.73 m² and 45 mL/min/1.73 m² [4]. The kappa values were interpreted as follows: <0.20, poor; 0.21-0.40, fair; 0.41-0.60, moderate; 0.61-0.80, good; and >0.81, very good [22]. In general, reduced GFR is defined as an eGFR <60 mL/min/1.73 m². Additionally, the KDIGO guideline recommends measuring CysC in adults with an eGFR of 45-59 mL/min/1.73 m², who do not have markers of kidney damage for confirmation of CKD [4]. Thus, we used two GFR cutoff points. The overall concordance rate (positive and negative) was also calculated for all equations.

Data were analyzed by using Analyse-it (Analyse-it Software Ltd., Leeds, UK) and MedCalc Statistical Software version 15.2.2 (MedCalc Software, Ostend, Belgium). P values ≤0.05 were considered statistically significant.

RESULTS

1. GFR category distribution in the study population
The baseline subject characteristics and calculated eGFR stratified by age groups are shown in Table 1. The CKD-EPI equations yielded higher mean eGFRs than the MDRD Study equation, and the degree of difference varied with the equations and categories. Weighted kappa value was determined to evaluate the degree of categorical agreement, and kappa value was determined for diagnostic agreement with GFR cutoffs of 60 mL/min/1.73 m² and 45 mL/min/1.73 m² [4]. The kappa values were interpreted as follows: <0.20, poor; 0.21-0.40, fair; 0.41-0.60, moderate; 0.61-0.80, good; and >0.81, very good [22]. In general, reduced GFR is defined as an eGFR <60 mL/min/1.73 m². Additionally, the KDIGO guideline recommends measuring CysC in adults with an eGFR of 45-59 mL/min/1.73 m², who do not have markers of kidney damage for confirmation of CKD [4]. Thus, we used two GFR cutoff points. The overall concordance rate (positive and negative) was also calculated for all equations.

Data were analyzed by using Analyse-it (Analyse-it Software Ltd., Leeds, UK) and MedCalc Statistical Software version 15.2.2 (MedCalc Software, Ostend, Belgium). P values ≤0.05 were considered statistically significant.

Table 1. Baseline subject characteristics and estimated glomerular filtration rates stratified by age group

| Variables          | 30-39 yr | 40-49 yr | 50-59 yr | 60-69 yr | 70-79 yr | Total |
|--------------------|----------|----------|----------|----------|----------|-------|
| Male %             | 46.7     | 55.0     | 45.4     | 47.4     | 49.0     | 48.9  |
| Age (yr)           | 35 (32-38) | 44 (42-46) | 54 (52-57) | 63 (61-66) | 72 (70-75) | 51 (42-59) |
| Body mass index (kg/m²) | 22.9 ± 3.8 | 23.7 ± 3.6 | 23.6 ± 3.1 | 23.9 ± 2.9 | 24.0 ± 3.2 | 23.6 ± 3.4 |
| HbA1c (%)         | 5.3 ± 0.4 | 5.6 ± 1.0 | 5.7 ± 0.8 | 6.0 ± 1.0 | 6.2 ± 1.5 | 5.7 ± 0.9 |
| Total cholesterol (mg/dL) | 190 ± 44   | 198 ± 46  | 204 ± 71  | 202 ± 78  | 195 ± 55  | 199 ± 61 |
| Triglyceride (mg/dL) | 95 ± 82    | 117 ± 102 | 101 ± 78  | 102 ± 62  | 106 ± 57  | 105 ± 83 |
| HDL-cholesterol (mg/dL) | 51 ± 14    | 49 ± 13   | 51 ± 17   | 50 ± 19   | 49 ± 15   | 50 ± 16 |
| LDL-cholesterol (mg/dL) | 116 ± 32   | 123 ± 33  | 133 ± 54  | 134 ± 62  | 122 ± 41  | 127 ± 47 |
| Serum Cr (mg/dL)   | 0.95 ± 0.20 | 0.97 ± 0.17 | 0.96 ± 0.23 | 0.99 ± 0.35 | 1.03 ± 0.25 | 0.97 ± 0.24 |
| Serum CysC (mg/l)  | 0.71 ± 0.14 | 0.73 ± 0.13 | 0.78 ± 0.15 | 0.86 ± 0.21 | 0.96 ± 0.23 | 0.78 ± 0.17 |
| eGFRCKD-EPI (mL/min/1.73 m²) | 80.1 ± 12.0 | 75.4 ± 10.2 | 72.0 ± 10.8 | 68.9 ± 12.6 | 64.4 ± 14.4 | 73.5 ± 12.2 |
| eGFRMDRD (mL/min/1.73 m²) | 82.9 ± 9.8  | 78.6 ± 8.8  | 73.2 ± 9.2  | 66.8 ± 10.7 | 58.9 ± 11.9 | 74.5 ± 11.6 |
| eGFRLM (mL/min/1.73 m²) | 92.1 ± 13.6 | 85.2 ± 11.7 | 79.1 ± 11.8 | 73.0 ± 13.2 | 65.8 ± 15.0 | 81.4 ± 14.5 |
| eGFRLM* (mL/min/1.73 m²) | 117.8 ± 12.7 | 112.5 ± 12.4 | 102.5 ± 14.1 | 91.6 ± 17.3 | 79.5 ± 19.1 | 104.7 ± 18.0 |
| eGFRMDRD* (mL/min/1.73 m²) | 106.1 ± 13.1 | 99.9 ± 11.8 | 91.7 ± 12.1 | 82.7 ± 14.6 | 73.2 ± 16.8 | 94.0 ± 15.9 |

All data except male % and age are expressed as mean ± standard deviation. Age is presented as median value (25th and 75th percentiles). Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; LM, Lund-Malmö; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Cr, creatinine; CysC, cystatin C.
Table 2. Frequency of glomerular filtration rate categories by five estimating equations

| GFR category (mL/min/1.73 m²) | Number (%) of subjects with each GFR category according to the estimating equations |
|-------------------------------|---------------------------------------------------------------------------------|
|                              | MDRD | CKD-EPI | CKD-EPI-CysC | CKD-EPI-CysC | LM revised |
| G1 ≥ 90                      | 119  (8.0) | 416 (28.0) | 1,212 (81.8) | 982 (66.2) | 109 (7.4) |
| G2 60-89                     | 1,224 (82.5) | 983 (66.3) | 235 (15.8) | 461 (31.1) | 1,254 (84.6) |
| G3a 45-59                    | 112 (7.5) | 58 (3.9) | 24 (1.6) | 26 (1.8) | 92 (6.2) |
| G3b 30-44                    | 20 (1.3) | 18 (1.2) | 10 (0.7) | 11 (0.7) | 14 (0.9) |
| G4 15-29                     | 6 (0.4) | 6 (0.4) | 1 (0.0) | 2 (0.1) | 12 (0.8) |
| G5 < 15                      | 1 (0.1) | 1 (0.1) | 0 (0.0) | 0 (0.0) | 1 (0.1) |
| Total                        | 1,482 (100.0) | 1,482 (100.0) | 1,482 (100.0) | 1,482 (100.0) | 1,482 (100.0) |

Abbreviations: GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; LM, Lund-Malmö; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Cr, creatinine; CysC, cystatin C.

Table 3. Agreement between MDRD Study equation and other equations

| GFR category | MDRD Study | G1 | G2 | G3a | G3b | G4 | G5 | Total | Categorical agreement | Diagnostic agreement at specific eGFR cutoffs |
|--------------|------------|----|----|-----|-----|----|----|-------|-----------------------|---------------------------------------------|
|              |            |    |    |     |     |    |    |       | % Weighted kappa (95% CI) | Kappa at 60 mL/min/1.73 m² (95% CI) Kappa at 45 mL/min/1.73 m² (95% CI) |
| CKD-EPI      |            |    |    |     |     |    |    |       |                       |                                             |
| G1           |            | 119| 297| 0   | 0   | 0  | 0  | 416   | 76.0                   | 0.521 (0.474-0.568) 0.729 (0.662-0.796) 0.961 (0.907-1.000) |
| G2           |            | 0  | 927| 56  | 0   | 0  | 0  | 983   |                        |                                             |
| G3a          |            | 0  | 0  | 56  | 2   | 0  | 0  | 58    |                        |                                             |
| G3b          |            | 0  | 0  | 0   | 18  | 0  | 0  | 18    |                        |                                             |
| G4           |            | 0  | 0  | 0   | 0   | 6  | 0  | 6     |                        |                                             |
| G5           |            | 0  | 0  | 0   | 0   | 0  | 1  | 1     |                        |                                             |
| CKD-EPI-CysC |            |    |    |     |     |    |    |       |                       |                                             |
| G1           |            | 113| 1,047| 43 | 7  | 2 | 0 | 1,212 | 20.3                   | 0.067 (0.047-0.087) 0.259 (0.173-0.346) 0.415 (0.217-0.613) |
| G2           |            | 4  | 169 | 54  | 4  | 0 | 0 | 235   |                        |                                             |
| G3a          |            | 2  | 7  | 13  | 2  | 0 | 0 | 24    |                        |                                             |
| G3b          |            | 0  | 1  | 2   | 6  | 0 | 1 | 10    |                        |                                             |
| G4           |            | 0  | 0  | 0   | 1   | 0 | 0 | 1     |                        |                                             |
| G5           |            | 0  | 0  | 0   | 0   | 0 | 0 | 0     |                        |                                             |
| CKD-EPI-CysC |            |    |    |     |     |    |    |       |                       |                                             |
| G1           |            | 113| 865 | 4   | 0  | 0 | 0 | 982   | 33.3                   | 0.139 (0.111-0.167) 0.402 (0.313-0.492) 0.595 (0.415-0.776) |
| G2           |            | 6  | 358 | 92  | 5  | 0 | 0 | 461   |                        |                                             |
| G3a          |            | 0  | 1  | 15  | 7  | 3 | 0 | 26    |                        |                                             |
| G3b          |            | 0  | 0  | 1   | 7  | 3 | 0 | 11    |                        |                                             |
| G4           |            | 0  | 0  | 0   | 1   | 0 | 1 | 2     |                        |                                             |
| G5           |            | 0  | 0  | 0   | 0   | 0 | 0 | 0     |                        |                                             |
| LM revised   |            |    |    |     |     |    |    |       |                       |                                             |
| G1           |            | 103| 6  | 0   | 0   | 0 | 0 | 109   | 93.8                   | 0.823 (0.788-0.859) 0.737 (0.674-0.799) 0.962 (0.910-1.000) |
| G2           |            | 16 | 1,197 | 41 | 0  | 0 | 0 | 1,254 |                        |                                             |
| G3a          |            | 0  | 21 | 70  | 1  | 0 | 0 | 92    |                        |                                             |
| G3b          |            | 0  | 0  | 1   | 13 | 0 | 0 | 14    |                        |                                             |
| G4           |            | 0  | 0  | 0   | 6   | 6 | 0 | 12    |                        |                                             |
| G5           |            | 0  | 0  | 0   | 0   | 0 | 1 | 1     |                        |                                             |
| Total        |            | 119| 1,224 | 112 | 20 | 6 | 1 | 1,482 |                        |                                             |

Abbreviations: CI, confidence interval; See Table 1.
age groups. The eGFR_{CKD-EPI\_CysC} (104.7 mL/min/1.73 m²) was the highest, followed by eGFR_{CKD-EPI\_Cr-CysC} (94.0 mL/min/1.73 m²), eGFR_{CKD-EPI\_Cr} (81.4 mL/min/1.73 m²), eGFR_{LM\_Revised} (74.5 mL/min/1.73 m²), and eGFR_{MDRD\_Revised} (73.5 mL/min/1.73 m²). In older patients (≥ 60 yr), the LM\_Revised equation yielded a lower eGFR than the MDRD Study equation. For all equations, a decreasing eGFR trend was observed as age increased.

The frequencies of the subjects in each GFR category are shown in Table 2. The proportion of each GFR category varied considerably between equations, especially for categories G1 and G2. The proportions of G1 were 8.0% (MDRD), 28.0% (CKD-EPI\_Cr), 81.7% (CKD-EPI\_Cr-CysC), 66.2% (CKD-EPI\_Cr\_CysC), and 7.4% (LM\_Revised), and the proportions of G2 were 82.5% (MDRD), 66.3% (CKD-EPI\_Cr), 15.8% (CKD-EPI\_Cr-CysC), 31.1% (CKD-EPI\_Cr\_CysC), and 84.6% (LM\_Revised).

2. Concordance between MDRD Study equation and other equations

Categorical agreement rates between the MDRD Study and other equations ranged from 20.3 to 93.8%. Upward reclassification from G2 (MDRD Study equation) to G1 (CKD-EPI equations) was common, especially for CKD-EPI\_Cr-CysC and CKD-EPI\_Cr\_CysC equations (Table 3). Weighted kappa values were fair to good in serum Cr-based equations, but poor in CysC-containing equations.

For diagnostic agreement, kappa values at two eGFR cutoffs were variable depending on the equation. Kappa values were better at cutoff 45 mL/min/1.73 m² than 60 mL/min/1.73 m². For all equations, overall concordance rates were greater than 90% when the GFR cutoff of 60 mL/min/1.73 m² was used (96.2% for CKD-EPI\_Cr, 91.6% for CKD-EPI\_Cr-CysC, 93.1% for CKD-EPI\_Cr\_CysC, and 95.8% for LM\_Revised), or when 45 mL/min/1.73 m² was used (99.9% for CKD-EPI\_Cr, 98.5% for CKD-EPI\_Cr\_CysC, 98.9% for CKD-EPI\_Cr-CysC, and 99.9% for LM\_Revised).

The mean eGFR difference (calculated by: GFR by MDRD Study equation-GFR by other equations) was largest in the CKD-EPI\_Cr\_CysC equation (-31.4, Fig. 1); it was significantly larger than the differences of other equations compared with the MDRD Study equation (P < 0.001). The r coefficients were 0.936 for LM\_Revised, 0.972 for CKD-EPI\_Cr, 0.494 for CKD-EPI\_Cr\_CysC, and 0.806 for CKD-EPI\_Cr-CysC equations (P < 0.001).

3. Prevalence of reduced eGFR

The prevalence of reduced GFR (< 60 mL/min/1.73 m², which corresponds to GFR categories G3a-G5) according to the age group and gender are presented in Table 4. In total, the prevalence of reduced GFR was the highest according to the MDRD Study equation (9.4%) and the lowest (2.4%) according to the CKD-EPI\_Cr\_CysC equation. The prevalence increased as age increased in all equations. Of note, a very high percentage of low GFR (45.9%) was noted in patients in their 70's according to the LM\_Revised equation.

DISCUSSION

The Cr-based CKD-EPI equation is recommended for the initial assessment of GFR, and CysC-based CKD-EPI equations can be used for confirmation of kidney disease according to the KDIGO guidelines [4, 23]. In this study, we compared five eGFR equations, including CysC-based formulas, in the Korean population. The prevalence of reduced GFR by CysC-based CKD-EPI equations has not been reported in Korea yet.

The eGFR classification differed considerably according to the equation used for estimation, especially between CKD-EPI\_Cr-CysC or CKD-EPI\_Cr\_CysC equations compared with the MDRD Study equation. Most of the study population (>80%) were in the G2 category (60-89 mL/min/1.73 m²) according to the MDRD Study equation, but in G1 (≥ 90 mL/min/1.73 m²) according to the CKD-EPI\_Cr\_CysC equation. The reason for this discrepancy might be related to the eGFR distribution of the study population. Mean eGFR\_MDRD was 73.5 mL/min/1.73 m² with a standard deviation of 12.2 mL/min/1.73 m²; thus, there were many results around the cutoff value of 90 mL/min/1.73 m². In addition, the CKD-EPI\_Cr\_CysC and CKD-EPI\_Cr\_CysC equations yielded systematically higher eGFR results (mean difference 31.4 mL/min/1.73 m² and 20.6 mL/min/1.73 m², respectively) in comparison with the MDRD Study equation. This finding was in line with previous studies. In the US National Health and Nutrition Examination Survey (NHANES) 1999-2002 data, the distribution of eGFR\_MDRD\_EPI\_CysC was broader and shifted to the right compared with that of eGFR\_MDRD [24]. Thus, upward reclassification might be common in CysC-based equations.

All equations, except for the CKD-EPI\_Cr\_CysC equation, showed good correlation with the MDRD Study equation. CKD-EPI\_Cr\_CysC showed only a moderate correlation (r = 0.49). The three different CKD-EPI equations showed an overall low prevalence of reduced GFR compared with the MDRD Study equation, especially according to the two CysC-containing equations. The LM\_Revised equation was recently reported to outperform the MDRD Study and CKD-EPI equations in a Swedish population [15]; however, there has been no evaluation of this equation in the Asian population. It yielded similar mean eGFR results com-

---

http://dx.doi.org/10.3343/alm.2016.36.6.521
Comparison of five eGFRs

pared with the MDRD Study equation; these two equations showed a very high correlation and a similar prevalence of reduced GFR. However, eGFR was underestimated in patients ≥ 60 yr, when using the LM_Revised equation. This observation needs to be subjected to further studies because of the increased possibility of co-morbidities in older patients. The LM_Revised equation was generated only from the Swedish population; hence, ethnic differences might have influenced GFR estimation as well.

Although the CKD-EPI_{Cr} equation is recommended by KDIGO for initial GFR assessment, newer GFR estimating equations have been developed and validated, including a Korean version of the CKD-EPI_{Cr} equation [25], a serum Cr-based full age spectrum equation [26], and a CysC-based equation based on a Caucasian, Asian, pediatric, and adult population (CAPA) [27]. Our study did not aim to compare all recent equations; however, we analyzed the CysC-based CAPA equation briefly. The mean eGFR_{CAPA} (106.3 mL/min/1.73 m²), eGFR difference in comparison with MDRD Study equation (-32.9), and prevalence of eGFR less than 60 mL/min/1.73 m² (2.7%) were similar when compared with CKD-EPI_{CysC} equation.

The prevalence of reduced GFR has been reported differently depending on the study population and the GFR-estimating equation used. In several previous studies, there were clinically significant differences in the prevalence of stage 3 or higher CKD depending on the equation used to estimate GFR. Delanaye et al [20] reported that the prevalence of eGFR less than 60 mL/min/1.73 m² was the highest for eGFR_{MDRD} (13%), intermediate for eGFR_{CKD-EPI_{Cr}} (9.8%), and the lowest for eGFR_{CKD-EPI_{CysC}} (8.7%).

Fig. 1. Bland-Altman plots of estimated glomerular filtration rate (eGFR) calculated by the MDRD Study equation and others (n=1,482). (A) CKD-EPI_{Cr} equation. (B) LM_Revised equation. (C) CKD-EPI_{CysC} equation. (D) CKD-EPI_{Cr-CysC} equation. The solid gray lines represent the mean difference and dashed lines depict ±1.96 SD. A negative difference suggests an overestimation of GFR by each equation compared with the value obtained by the MDRD Study equation. For ease of display, the maximum scale on the vertical axis of (A) and (B) was limited to 30, while that on (C) and (D) was limited to 90 depending on the distribution of the eGFR difference between equations.
Comparison of five eGFRs

Table 4. Prevalence of reduced eGFR (<60 mL/min/1.73 m²) based on the five equations, stratified by age group and sex*

| Age (yr) | Total (n = 1,482) | Male (n = 725) | Female (n = 757) |
|---------|------------------|----------------|-----------------|
| MDRD    |                  |                |                 |
| 30-39   | 6 (2.2)          | 2 (1.6)        | 4 (2.7)         |
| 40-49   | 17 (4.1)         | 8 (3.5)        | 9 (4.9)         |
| 50-59   | 46 (10.6)        | 21 (10.7)      | 25 (10.6)       |
| 60-69   | 45 (15.6)        | 17 (12.4)      | 28 (18.4)       |
| 70-79   | 25 (33.8)        | 10 (27.8)      | 15 (39.4)       |
| Total   | 139 (9.4)        | 58 (8.0)       | 81 (10.7)       |
| LMrev    |                  |                |                 |
| 30-39   | 2 (0.7)          | 1 (0.8)        | 1 (0.7)         |
| 40-49   | 6 (1.5)          | 2 (0.9)        | 4 (2.2)         |
| 50-59   | 24 (5.6)         | 17 (8.7)       | 7 (3.0)         |
| 60-69   | 53 (18.3)        | 29 (21.2)      | 24 (15.8)       |
| 70-79   | 34 (45.9)        | 16 (44.4)      | 18 (47.4)       |
| Total   | 83 (5.6)         | 39 (5.4)       | 44 (5.8)        |
| CKD-EPIr |                  |                |                 |
| 30-39   | 2 (0.7)          | 0 (0.0)        | 1 (0.7)         |
| 40-49   | 1 (0.2)          | 1 (0.4)        | 0 (0.0)         |
| 50-59   | 7 (1.6)          | 5 (2.6)        | 2 (0.8)         |
| 60-69   | 14 (4.8)         | 9 (6.5)        | 5 (3.3)         |
| 70-79   | 11 (14.9)        | 7 (13.9)       | 4 (10.5)        |
| Total   | 35 (2.4)         | 22 (3.0)       | 13 (1.7)        |
| CKD-EPIc |                  |                |                 |
| 30-39   | 2 (0.7)          | 1 (0.8)        | 1 (0.7)         |
| 40-49   | 0 (0.0)          | 0 (0.0)        | 0 (0.0)         |
| 50-59   | 7 (1.6)          | 7 (3.6)        | 0 (0.0)         |
| 60-69   | 15 (5.2)         | 9 (6.6)        | 6 (3.9)         |
| 70-79   | 15 (20.3)        | 7 (19.4)       | 8 (21.1)        |
| Total   | 39 (2.6)         | 24 (3.3)       | 15 (2.0)        |

*GFR categories G3a-G5 correspond to GFR <60 mL/min/1.73 m². Abbreviations: See Table 1.

Cr-CysC (5%) and eGFR_{CKD-EPIc} (4.7%) in 4,189 Belgian patients over 50 yr old. This prevalence trend was similar to ours. One Japanese study showed a 2-fold difference of prevalence between the MDRD Study and CKD-EPIr equations (12.8 vs 6.5%), by studying over 26,000 participants who underwent annual health check-ups [16]. Lujambio et al [28] reported that the prevalence of eGFR less than 60 mL/min/1.73 m² was the highest for eGFR_{CKD-EPIc} (21.8%), intermediate for eGFR_{CKD-EPIc,CysC} (11.8%), and the lowest for eGFR_{MDRD} (5.9%) and eGFR_{MDRD} (3.4%) in 119 Uruguayans.

In the US, the prevalence of reduced GFR (eGFR <60 mL/min/1.73 m²) by CKD-EPIr equation was reported to be 4.7% from 1988-1994 and 6.5% from 1999-2002 from NHANES data [29]. In Korea, the prevalence of reduced GFR by the CKD-EPIr equation has been reported as 7.7% in 2007 and 2.6% in 2010 from Korea NHANES data [17, 18]. In this study, it was 5.1% of the whole study population. This difference could be due to the following reasons. First, the proportion of younger individuals under 40 yr old was lower than that in other studies (23% vs 30-32%). Compared with 2010 Korea NHANES data, the mean eGFR was relatively lower in this study (81.4 mL/min/1.73 m² vs 95.9-96.8 mL/min/1.73 m²), resulting in higher prevalence of reduced GFR compared with other studies. Second, the study period was different (2014 vs 2007-2010), although the impact of this on the prevalence is still uncertain.

Our retrospective study has several limitations. First, we compared all the eGFR equations to the MDRD Study equation, because of the absence of GFR data measured by the gold standard method [18]. Therefore, it was impossible to evaluate the accuracy. The magnitude of bias, calculated by measured GFR-calculated GFR was previously reported to be 2.5-5.8 mL/min/1.73 m², and this difference could influence the prevalence of CKD stages [17, 24]. Second, our population might not be representative of the entire population of Korea. Third, we could not analyze albuminuria data or other markers of kidney damage. The classification of CKD was not performed, which is based on both GFR category and albuminuria category. Thus, there could be the CKD patients among the subjects with eGFR ≥60 mL/min/1.73 m².

In conclusion, this is the first study that compared five eGFR equations in the Korean population. Our data demonstrated remarkable differences in GFR assessment depending on the equation used. The proportion of each GFR category varied considerably, and CysC-containing equations yielded higher eGFRs and showed larger differences compared with the MDRD Study equation. The prevalence of reduced GFR was lowered by the CKD-EPI equations. Further studies using prospective design and in various ethnicities are necessary.
Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Acknowledgments

This study was supported by Konkuk University in 2016.

REFERENCES

1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72:247-59.
2. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA 2015;313:837-46.
3. Carville S, Wonderling D, Stevens P, Guideline Development Group. Early identification and management of chronic kidney disease in adults: summary of updated NICE guidance. BMJ 2014;349:g4507.
4. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf (Updated on Jan 2013).
5. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713-35.
6. Akbari A, Clase CM, Acott P, Battistella M, Bello A, Feltmate P, et al. Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management. Am J Kidney Dis 2015;65:177-205.
7. College of American Pathologists. Practices and recommendations for reporting estimated glomerular filtration rate (eGFR). http://www.cap.org/ShowProperty?nodePath=UCMContribution%20Folders/WebContent/pdf/current-status-reporting-egfr-2013.pdf (Accessed on Apr 1, 2016).
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
9. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;144:247-54.
10. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
11. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-9.
12. Delanaye P, Cavalier E, Cristol JP, Delanghe JR. Calibration and precision of serum creatinine and plasma cystatin C measurement: impact on the estimation of glomerular filtration rate. J Nephrol 2014;27:467-75.
13. Björk J, Grubb A, Sterner G, Nyman U. Revised equations for estimating glomerular filtration rate based on the Lund-Malmö Study cohort. Scand J Clin Lab Invest 2011;71:232-9.
14. Björk J, Jones I, Nyman U, Sjöström P. Validation of the Lund-Malmö, Chronic Kidney Disease Epidemiology (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) equations to estimate glomerular filtration rate in a large Swedish clinical population. Scand J Urol Nephrol 2012;46:212-22.
15. Nyman U, Grubb A, Larsson A, Hansson LO, Flodin M, Nordin G, et al. The revised Lund-Malmö GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population. Clin Chem Lab Med 2014;52:815-24.
16. Ohsawa M, Tanno K, Itai K, Turin TC, Okamura T, Ogawa A, et al. Concordance of CKD stages in estimation by the CKD-EPI equation and estimation by the MDRD equation in the Japanese general population: the Iwate KENCO Study. Int J Cardiol 2013;165:377-9.
17. Jeong TD, Lee W, Chun S, Lee SK, Ryu JS, Min WK, et al. Comparison of the MDRD study and CKD-EPI equations for the estimation of the glomerular filtration rate in the Korean general population: the fifth Korea National Health and Nutrition Examination Survey (KNHANES V-1). 2010. Korea Blood Press Res 2013;37:443-50.
18. Shin SY, Kwon MJ, Park H, Woo HY. Comparison of chronic kidney disease prevalence examined by the chronic kidney disease epidemiology collaboration equation with that by the modification of diet in renal disease equation in Korean adult population. J Clin Lab Anal 2014;28:320-7.
19. Shafi T, Matsushita K, Selvin E, Sang Y, Astor BC, Inker LA, et al. Comparing the association of GFR estimated by the CKD-EPI and MDRD study equations and mortality: the third national health and nutrition examination survey (NHANES III). BMC Nephrol 2012;13:42.
20. Delanaye P, Cavalier E, Moranne O, Lutteri L, Krzesinski JM, Bruyère O. Creatinine- or cystatin C-based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease. BMC Nephrol 2013;14:57.
21. Taylor R. Interpretation of the correlation coefficient: a basic review. J Diagn Med Sonogr 1990;6:35-9.
22. Altman DG. Practical statistics for medical research. New York: Chapman and Hall, 1991.
23. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Inter (Suppl) 2012;2:1-138. http://www.kdigo.orgclinical_practice_guidelines/pdf/KDIGO%20AKI%20Guideline.pdf (Updated on Mar 2012).
24. Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis 2014;63:820-34.
25. Jeong TD, Lee W, Yun YM, Chun S, Song J, Min WK. Development and validation of the Korean version of CKD-EPI equation to estimate glomerular filtration rate. Clin Biochem 2016;49:713-9.
26. Pottel H, Hoste L, Dubourg L, Ebert N, Schaeffner E, Eriksen BO, et al. An estimated glomerular filtration rate equation for the full age spectrum. Nephrol Dial Transplant 2016;31:798-806.
27. Björk J, Grubb A, Larsson A, Hansson LO, Flodin M, Sterner G, et al. Accuracy of GFR estimating equations combining standardized cystatin C and creatinine assays: a cross-sectional study in Sweden. Clin Chem Lab Med 2015;53:403-14.
28. Lujambio I, Sottolano M, Luzardo L, Robaina S, Krul N, Thijs L, et al. Estimation of glomerular filtration rate based on the Lund-Malmö Study cohort. Scand J Clin Lab Invest 2011;71:232-9.